According to a corporate disclosure made to the Korean Exchange by Samsung Biologics, the company has entered into its largest contract manufacturing organisation (CMO) deal to date with an unnamed US based pharmaceutical company valued at USD $1.06b. The contract extends until 31 December 2030 and is said to significantly boost Samsung Biologics’ annual order volume, reflecting a 40% increase over the previous year’s total orders.
This follows Samsung Biologics’ contract manufacturing agreement with Kiniksa Pharmaceuticals last month and the announcement, on 7 February 2024 that Samsung Biologics has partnered with Lego Chem Biosciences to develop and manufacture ADCs.